Begin with the gap
Most of the world's most important biomedical breakthroughs — precision genomics, CAR-T cell therapy, autologous gene therapy — remain locked inside a small number of high-resource markets. Patients elsewhere either travel overseas at extreme cost, or they go without. We exist to close that gap. Not by selling technology as a product, but by transferring it as a capability.
The deliverable is local capacity
Trained teams, validated workflows, regulatory documentation and working facilities are the deliverables of capability transfer. VectorGene helps governments, hospitals, research institutes and biotech companies build local capability in genomics, CAR-T manufacturing, cell therapy and gene therapy.
The plasmid-transfer pathway
Proprietary viral vectors cannot be exported. VectorGene's approach enables local production through plasmid transfer.
This is VectorGene’s supplied pathway rationale, rather than a determination about every vector or jurisdiction. The pathway connects plasmid production, international transport, local fermentation, virus purification and cell transfection. Material rights, transport requirements and local permissions need to be reviewed for the specific programme.
Regulatory ownership stays local
No. Regulatory approval is the responsibility of the local partner and is conducted through the national regulatory authority of the host country. VectorGene supports the documentation, technical files, evidence packages and submission preparation — but the formal application and ownership of the regulatory dossier remain with the local institution.
Feasibility before commitment
Disease burden analysis, regulatory landscape review, infrastructure audit and commercial feasibility before any commitments are made.
A globally connected precision medicine ecosystem — so patients worldwide can access advanced diagnostics and next-generation treatments closer to home.
